Teva Pharmaceutical Industries (NYSE:TEVA) Trading Up 0.5%

Teva Pharmaceutical Industries Ltd (NYSE:TEVA)’s share price was up 0.5% on Monday . The company traded as high as $10.28 and last traded at $10.25, approximately 13,467,456 shares were traded during mid-day trading. A decline of 47% from the average daily volume of 25,398,352 shares. The stock had previously closed at $10.20.

A number of research analysts recently weighed in on TEVA shares. JPMorgan Chase & Co. upgraded Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and set a $8.00 target price on the stock in a report on Tuesday, November 12th. Gabelli upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a report on Wednesday, October 16th. Raymond James reduced their target price on Teva Pharmaceutical Industries from $22.00 to $15.00 and set an “outperform” rating on the stock in a report on Thursday, August 8th. Wells Fargo & Co reduced their target price on Teva Pharmaceutical Industries from $17.00 to $8.00 and set a “market perform” rating on the stock in a report on Monday, September 30th. Finally, Royal Bank of Canada reiterated a “hold” rating and issued a $10.00 target price on shares of Teva Pharmaceutical Industries in a report on Thursday, August 8th. Five investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $10.83.

The firm has a market capitalization of $10.23 billion, a PE ratio of 3.69, a price-to-earnings-growth ratio of 1.00 and a beta of 1.73. The company has a debt-to-equity ratio of 1.62, a current ratio of 0.89 and a quick ratio of 0.56. The stock has a 50-day moving average price of $7.79 and a 200-day moving average price of $8.74.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.56 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.58 by ($0.02). The firm had revenue of $4.26 billion during the quarter, compared to the consensus estimate of $4.25 billion. Teva Pharmaceutical Industries had a negative net margin of 22.88% and a positive return on equity of 15.41%. As a group, equities research analysts predict that Teva Pharmaceutical Industries Ltd will post 2.26 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently modified their holdings of the company. First Interstate Bank bought a new stake in Teva Pharmaceutical Industries during the second quarter worth approximately $28,000. Pacer Advisors Inc. bought a new position in shares of Teva Pharmaceutical Industries in the second quarter valued at $32,000. AdvisorNet Financial Inc increased its holdings in shares of Teva Pharmaceutical Industries by 71.3% in the third quarter. AdvisorNet Financial Inc now owns 3,665 shares of the company’s stock valued at $25,000 after buying an additional 1,525 shares in the last quarter. Kavar Capital Partners LLC bought a new position in shares of Teva Pharmaceutical Industries in the second quarter valued at $35,000. Finally, Motco bought a new position in shares of Teva Pharmaceutical Industries in the third quarter valued at $28,000. Institutional investors and hedge funds own 57.81% of the company’s stock.

Teva Pharmaceutical Industries Company Profile (NYSE:TEVA)

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Further Reading: Convertible Shares

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.